Vicore Pharma Holding AB (publ)
VICO.ST
Price:
$10.28
Market Cap:
$2.41B
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the de...[Read more]
Industry
Biotechnology
IPO Date
2015-12-10
Stock Exchange
STO
Ticker
VICO.ST
PE Ratio
[-5.33]
ROE
[-44.02%]
Current Ratio
[13.86]
Dividend Yield
[0%]
Enterprise Value
[1.94B]
Dividend History
The ROE as of December 2025 (TTM) for Vicore Pharma Holding AB (publ) (VICO.ST) is -44.02%
According to Vicore Pharma Holding AB (publ)’s latest financial reports and current stock price. The company's current ROE is -44.02%. This represents a change of 288.85% compared to the average of -11.32% of the last 4 quarters.
Vicore Pharma Holding AB (publ) (VICO.ST) Historical ROE (quarterly & annually)
How has VICO.ST ROE performed in the past?
The mean historical ROE of Vicore Pharma Holding AB (publ) over the last ten years is -36.41%. The current -44.02% ROE has changed 20.93% with respect to the historical average. Over the past ten years (40 quarters), VICO.ST's ROE was at its highest in in the March 2024 quarter at 6.49%. The ROE was at its lowest in in the September 2022 quarter at -42.61%.
Average
-36.41%
Median
-21.94%
Minimum
-99.77%
Maximum
-5.58%
Vicore Pharma Holding AB (publ) (VICO.ST) ROE by Quarter and Year
Discovering the peaks and valleys of Vicore Pharma Holding AB (publ) ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 281.06%
Maximum Annual ROE = -5.58%
Minimum Annual Increase = -121.88%
Minimum Annual ROE = -99.77%
| Year | ROE | Change |
|---|---|---|
| 2024 | -14.93% | -78.13% |
| 2023 | -68.28% | -31.56% |
| 2022 | -99.77% | 28.99% |
| 2021 | -77.35% | 86.71% |
| 2020 | -41.43% | 43.12% |
| 2019 | -28.94% | 281.06% |
| 2018 | -7.60% | -33.25% |
| 2017 | -11.38% | 29.32% |
| 2016 | -8.80% | 57.75% |
| 2015 | -5.58% | -121.88% |
Vicore Pharma Holding AB (publ) (VICO.ST) Average ROE
How has VICO.ST ROE performed in the past?
The current ROE of Vicore Pharma Holding AB (publ) (VICO.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-60.99%
5-year avg
-60.35%
10-year avg
-36.41%
Vicore Pharma Holding AB (publ) (VICO.ST) ROE vs. Peers
How is VICO.ST’s ROE compared to its peers?
Vicore Pharma Holding AB (publ)’s ROE is less than Hansa Biopharma AB (publ) (115.70%), greater than Egetis Therapeutics AB (publ) (-85.57%), greater than BioInvent International AB (publ) (-41.14%), less than Saniona AB (publ) (105.88%), greater than Diamyd Medical AB (publ) (-77.85%), less than Oncopeptides AB (publ) (9.01%), less than Humana AB (publ) (7.55%), less than Cantargia AB (publ) (108.71%), greater than SynAct Pharma AB (-54.05%), greater than Xspray Pharma AB (publ) (-36.36%),
| Company | ROE | Market cap |
|---|---|---|
| 115.70% | $2.83B | |
| -85.57% | $1.66B | |
| -41.14% | $1.90B | |
| 105.88% | $2.71B | |
| -77.85% | $1.29B | |
| 9.01% | $1.15B | |
| 7.55% | $2.31B | |
| 108.71% | $944.72M | |
| -54.05% | $1.10B | |
| -36.36% | $1.19B |
Build a custom stock screener for Vicore Pharma Holding AB (publ) (VICO.ST) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vicore Pharma Holding AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Vicore Pharma Holding AB (publ) (VICO.ST) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Vicore Pharma Holding AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Vicore Pharma Holding AB (publ)'s ROE?
How is the ROE calculated for Vicore Pharma Holding AB (publ) (VICO.ST)?
What is the highest ROE for Vicore Pharma Holding AB (publ) (VICO.ST)?
What is the 3-year average ROE for Vicore Pharma Holding AB (publ) (VICO.ST)?
What is the 5-year average ROE for Vicore Pharma Holding AB (publ) (VICO.ST)?
How does the current ROE for Vicore Pharma Holding AB (publ) (VICO.ST) compare to its historical average?